Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 49 to 53 of 53 entries
Sorted by: Best Match Show Resources per page
Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial.

PloS one

Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, Bravo C.
PMID: 34941934
PLoS One. 2021 Dec 23;16(12):e0260881. doi: 10.1371/journal.pone.0260881. eCollection 2021.

BACKGROUND: Chronic Lung Allograft Dysfunction (CLAD) is a major obstacle for long term survival after lung transplantation (LTx). Besides Bronchiolitis Obliterans Syndrome, two other phenotypes of CLAD, restrictive allograft syndrome (RAS) and mixed phenotype, have been described. Trials to...

Cite
Gottlieb J, Verleden GM, Perchl M, et al. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS One. 2021;16(12):e0260881doi: 10.1371/journal.pone.0260881.
Gottlieb, J., Verleden, G. M., Perchl, M., Valtin, C., Vallee, A., Brugière, O., & Bravo, C. (2021). Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PloS one, 16(12), e0260881. https://doi.org/10.1371/journal.pone.0260881
Gottlieb, Jens, et al. "Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial." PloS one vol. 16,12 (2021): e0260881. doi: https://doi.org/10.1371/journal.pone.0260881
Gottlieb J, Verleden GM, Perchl M, Valtin C, Vallee A, Brugière O, Bravo C. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS One. 2021 Dec 23;16(12):e0260881. doi: 10.1371/journal.pone.0260881. eCollection 2021. PMID: 34941934; PMCID: PMC8700042.
Copy Download .nbib Format: NLM
Case Report: Multimodal Functional and Structural Evaluation Combining Pre-operative nTMS Mapping and Neuroimaging With Intraoperative CT-Scan and Brain Shift Correction for Brain Tumor Surgical Resection.

Frontiers in human neuroscience

Senova S, Lefaucheur JP, Brugières P, Ayache SS, Tazi S, Bapst B, Abhay K, Langeron O, Edakawa K, Palfi S, Bardel B.
PMID: 33716700
Front Hum Neurosci. 2021 Feb 25;15:646268. doi: 10.3389/fnhum.2021.646268. eCollection 2021.

No abstract available.

Cite
Senova S, Lefaucheur JP, Brugières P, et al. Case Report: Multimodal Functional and Structural Evaluation Combining Pre-operative nTMS Mapping and Neuroimaging With Intraoperative CT-Scan and Brain Shift Correction for Brain Tumor Surgical Resection. Front Hum Neurosci. 2021;15:646268doi: 10.3389/fnhum.2021.646268.
Senova, S., Lefaucheur, J. P., Brugières, P., Ayache, S. S., Tazi, S., Bapst, B., Abhay, K., Langeron, O., Edakawa, K., Palfi, S., & Bardel, B. (2021). Case Report: Multimodal Functional and Structural Evaluation Combining Pre-operative nTMS Mapping and Neuroimaging With Intraoperative CT-Scan and Brain Shift Correction for Brain Tumor Surgical Resection. Frontiers in human neuroscience, 15646268. https://doi.org/10.3389/fnhum.2021.646268
Senova, Suhan, et al. "Case Report: Multimodal Functional and Structural Evaluation Combining Pre-operative nTMS Mapping and Neuroimaging With Intraoperative CT-Scan and Brain Shift Correction for Brain Tumor Surgical Resection." Frontiers in human neuroscience vol. 15 (2021): 646268. doi: https://doi.org/10.3389/fnhum.2021.646268
Senova S, Lefaucheur JP, Brugières P, Ayache SS, Tazi S, Bapst B, Abhay K, Langeron O, Edakawa K, Palfi S, Bardel B. Case Report: Multimodal Functional and Structural Evaluation Combining Pre-operative nTMS Mapping and Neuroimaging With Intraoperative CT-Scan and Brain Shift Correction for Brain Tumor Surgical Resection. Front Hum Neurosci. 2021 Feb 25;15:646268. doi: 10.3389/fnhum.2021.646268. eCollection 2021. PMID: 33716700; PMCID: PMC7947337.
Copy Download .nbib Format: NLM
ALK inhibitors for ALK-altered paediatric malignancies.

The Lancet. Oncology

Brugieres L, Afify Z, Lowe E.
PMID: 34780708
Lancet Oncol. 2021 Dec;22(12):1646-1648. doi: 10.1016/S1470-2045(21)00608-2. Epub 2021 Nov 12.

No abstract available.

Cite
Brugieres L, Afify Z, Lowe E. ALK inhibitors for ALK-altered paediatric malignancies. Lancet Oncol. 2021;22(12):1646-1648doi: 10.1016/S1470-2045(21)00608-2.
Brugieres, L., Afify, Z., & Lowe, E. (2021). ALK inhibitors for ALK-altered paediatric malignancies. The Lancet. Oncology, 22(12), 1646-1648. https://doi.org/10.1016/S1470-2045(21)00608-2
Brugieres, Laurence, et al. "ALK inhibitors for ALK-altered paediatric malignancies." The Lancet. Oncology vol. 22,12 (2021): 1646-1648. doi: https://doi.org/10.1016/S1470-2045(21)00608-2
Brugieres L, Afify Z, Lowe E. ALK inhibitors for ALK-altered paediatric malignancies. Lancet Oncol. 2021 Dec;22(12):1646-1648. doi: 10.1016/S1470-2045(21)00608-2. Epub 2021 Nov 12. PMID: 34780708.
Copy Download .nbib Format: NLM
A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome.

The European respiratory journal

Parquin F, Zuber B, Vallée A, Taupin JL, Cuquemelle E, Malard S, Neuville M, Devaquet J, Le Guen M, Fessler J, Beaumont L, Picard C, Hamid A, Colin de Verdière S, Grenet D, De Miranda S, Glorion M, Sage E, Pricopi C, De Wolf J, Brun AL, Longchampt E, Cerf C, Roux A, Brugière O.
PMID: 34016620
Eur Respir J. 2021 Nov 18;58(5). doi: 10.1183/13993003.04090-2020. Print 2021 Nov.

BACKGROUND: Pre-formed donor-specific antibodies (DSAs) are associated with worse outcome after lung transplantation (LTx) and might limit access to LTx. A virtual crossmatch-based strategy for perioperative desensitisation protocol has been used for immunised LTx candidates since 2012 at Foch...

Cite
Parquin F, Zuber B, Vallée A, et al. A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome. Eur Respir J. 2021;58(5)doi: 10.1183/13993003.04090-2020.
Parquin, F., Zuber, B., Vallée, A., Taupin, J. L., Cuquemelle, E., Malard, S., Neuville, M., Devaquet, J., Le Guen, M., Fessler, J., Beaumont, L., Picard, C., Hamid, A., Colin de Verdière, S., Grenet, D., De Miranda, S., Glorion, M., Sage, E., Pricopi, C., De Wolf, J., Brun, A. L., Longchampt, E., Cerf, C., Roux, A., & Brugière, O. (2021). A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome. The European respiratory journal, 58(5), . https://doi.org/10.1183/13993003.04090-2020
Parquin, Francois, et al. "A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome." The European respiratory journal vol. 58,5 (2021). doi: https://doi.org/10.1183/13993003.04090-2020
Parquin F, Zuber B, Vallée A, Taupin JL, Cuquemelle E, Malard S, Neuville M, Devaquet J, Le Guen M, Fessler J, Beaumont L, Picard C, Hamid A, Colin de Verdière S, Grenet D, De Miranda S, Glorion M, Sage E, Pricopi C, De Wolf J, Brun AL, Longchampt E, Cerf C, Roux A, Brugière O. A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome. Eur Respir J. 2021 Nov 18;58(5). doi: 10.1183/13993003.04090-2020. Print 2021 Nov. PMID: 34016620.
Copy Download .nbib Format: NLM
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.

Blood

Karaca Atabay E, Mecca C, Wang Q, Ambrogio C, Mota I, Prokoph N, Mura G, Martinengo C, Patrucco E, Leonardi G, Hossa J, Pich A, Mologni L, Gambacorti-Passerini CB, Brugieres L, Geoerger B, Turner SD, Voena C, Cheong TC, Chiarle R.
PMID: 34657149
Blood. 2021 Oct 17; doi: 10.1182/blood.2020008136. Epub 2021 Oct 17.

Anaplastic large cell lymphomas (ALCLs) frequently carry oncogenic fusions involving the anaplastic lymphoma kinase (ALK) gene. Targeting ALK using tyrosine kinase inhibitors (TKIs) is a therapeutic option in cases relapsed after chemotherapy, but TKI resistance may develop. By applying...

Cite
Karaca Atabay E, Mecca C, Wang Q, et al. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2021;doi: 10.1182/blood.2020008136.
Karaca Atabay, E., Mecca, C., Wang, Q., Ambrogio, C., Mota, I., Prokoph, N., Mura, G., Martinengo, C., Patrucco, E., Leonardi, G., Hossa, J., Pich, A., Mologni, L., Gambacorti-Passerini, C. B., Brugieres, L., Geoerger, B., Turner, S. D., Voena, C., Cheong, T. C., & Chiarle, R. (2021). Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood, . https://doi.org/10.1182/blood.2020008136
Karaca Atabay, Elif, et al. "Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma." Blood vol. (2021). doi: https://doi.org/10.1182/blood.2020008136
Karaca Atabay E, Mecca C, Wang Q, Ambrogio C, Mota I, Prokoph N, Mura G, Martinengo C, Patrucco E, Leonardi G, Hossa J, Pich A, Mologni L, Gambacorti-Passerini CB, Brugieres L, Geoerger B, Turner SD, Voena C, Cheong TC, Chiarle R. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2021 Oct 17; doi: 10.1182/blood.2020008136. Epub 2021 Oct 17. PMID: 34657149.
Copy Download .nbib Format: NLM
Showing 49 to 53 of 53 entries